Entries |
Document | Title | Date |
20080199454 | Caspase inhibitor prodrugs - The present invention relates to compounds of formula I which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. This invention further relates to the release of caspase inhibitors from these compounds through selective bond cleavage. This invention further relates to pharmaceutical compositions comprising these compounds, which are particularly well-suited for treatment of caspase-mediated diseases, including inflammatory and degenerative diseases. This invention further relates to methods for preparing compounds of this invention. | 08-21-2008 |
20080206225 | Closed Container Comprising an Activated Factor VII Polypeptide, Processes for the Preparation of the Same, and a Kit and a Method for Use of the Kit - The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit. | 08-28-2008 |
20080206226 | AGENT FOR PROMOTING OSTEOGENESIS AND/OR INHIBITING BONE RESORPTION - Provided is a novel agent for promoting osteogenesis and/or inhibiting bone resorption, which: can be directly taken from daily meals by mouth for long periods without any trouble in taste; directly impart a promoting effect on osteogenesis and an inhibiting effect on bone resorption to the bone; and can be expected to have therapeutic effects for preventing or ameliorating/treating various bone diseases. The above agent includes, as an active ingredient, any one or more of β | 08-28-2008 |
20080206227 | FACTOR VII CONJUGATES FOR SELECTIVELY TREATING NEOVASCULARIZATION DISORDERS - Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, containing a photosensitizer and a targeting molecule such as factor VII (“fVII”), fVIIa, or modified fVII, which binds with high affinity and specificity to tissue factor (TF). TF is more highly expressed, abnormally expressed or specifically expressed on endothelial cells lining the luminal surface of pathological neovasculature, than on normal vasculature, thus providing a specific and accessible therapeutic target. Following administration of fVIIPD, the compound specifically binds to the pathological neovasculature of the eye by interaction of the targeting molecule with TF expressed by endothelial cells within abnormal blood vessels. The photosensitizer may then be activated with a non-thermal laser light for selective destruction of abnormal vasculature. | 08-28-2008 |
20080213244 | Glutamate Receptor Antagonists as Neuroprotectives - The invention relates to the use of inhibiting agents of t-PA-mediated activation of the glutamate receptor, for example of the NMDA type, as neuroprotectives. | 09-04-2008 |
20080213245 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 09-04-2008 |
20080254019 | Therapeutic Agents and Therapeutic Methods For Treating Injured Tissue - This invention provides therapeutic agents, transplants and therapeutic methods that can enhance the regeneration of injured tissue. This invention relates to agents, transplants and therapeutic methods for enhancing the migration and accumulation of mesenchymal stem cells in injured tissues and/or suppressing the diffusion of mesenchymal stem cells from injured tissues. | 10-16-2008 |
20080286258 | Bifeprunox mesylate maintenance dose compositions and methods for using the same - The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders. | 11-20-2008 |
20080286259 | USE OF ACTIVATED COAGULATION FACTOR VII FOR TREATING THROMBOLYTIC THERAPY-INDUCED MAJOR BLEEDINGS - Major bleedings induced by thrombolytic/fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or a functional derivative thereof. | 11-20-2008 |
20080299109 | MECHANISM OF ASTRICYTE-NEURON SIGNALING - The present invention relates to a novel communication mechanism between astrocytes and neurons at a synapse. More specifically, the present invention relates to a signaling mechanism between astrocytes and neurons, by activating astrocytic G-protein coupled receptors, thereby activating glutamate receptors on a membrane of neighboring postsynaptic neurons, resulting in increasing the level of intracellular Ca | 12-04-2008 |
20080305100 | Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain - Activated protein C (APC), a prodrug, and/or a variant of APC may be used to inhibit undesirable effects of plasminogen activator: e.g., apoptosis or cell death of neurons and endothelial cells, brain hemorrhage or intracerebral bleeding, and/or tissue damage in a subject's brain. Inhibition appears to act through the extrinsic pathway of death receptor signal transduction. This represents an improvement in treatment using plasminogen activator (e.g., fibrinolysis). By reducing undesirable effects, the window for fibrinolytic therapy by plasminogen activator may be widened. | 12-11-2008 |
20080311104 | STABILIZED THROMBIN COMPOSITIONS - Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more. | 12-18-2008 |
20080311105 | Reversibly Inactivated Acidified Plasmin - The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. | 12-18-2008 |
20080317736 | Methods for enlarging the diameter of a biological conduit in a human subject - The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 12-25-2008 |
20090004175 | Methods for Optimizing Forming Vlla-Based Hemostatic Treatment - The present invention relates to pharmacogenomic methods for optimizing prevention and treatment of bleeding episodes using therapeutic proteins such as, e.g., Vitamin K-dependent clotting factors. | 01-01-2009 |
20090004176 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE - The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of | 01-01-2009 |
20090004177 | Combination Treatment with t-PA Variant and Low Molecular Weight Heparin - The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin. | 01-01-2009 |
20090010917 | Therapeutic Agents Comprising Pro-Apoptotic Proteins - The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax. | 01-08-2009 |
20090017007 | LIQUID FACTOR VII COMPOSITION - Storage-stable aqueous pharmaceutical compositions comprising a Factor VII or Factor Vila polypeptide, a buffering agent, and zinc ions (Zn | 01-15-2009 |
20090022706 | SUBSTITUTED CYCLOHEXENES - Disclosed herein are substituted cyclohexene TLR4 signaling pathway modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 01-22-2009 |
20090041747 | Compounds for Stabilizing Factor VII Polypeptide Formulations - The invention relates to novel compounds with formula (I) and their use in stabilization of Factor VIIa or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof. | 02-12-2009 |
20090041748 | Fibrinogen-Based Tissue Adhesive Containing an Elastase Inhibitor - The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. | 02-12-2009 |
20090047273 | Method For Production of Recombinant Human Thrombin ['644] - The present invention relates to a method is provided for producing recombinant human thrombin from recombinant prothrombin using recombinant ecarin having the sequence SEQ ID NO 2 or a homologue thereof. | 02-19-2009 |
20090053193 | Use of Factor VIIa for the Treatment of Burn Trauma - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of burn trauma. | 02-26-2009 |
20090060897 | Systems for enlarging the diameter of a biological conduit in a human subject - The invention provides systems for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 03-05-2009 |
20090068168 | SUBSTITUTED AMINO ALCOHOLS - Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 03-12-2009 |
20090081185 | Apoptotic agents - A complex at least formed from at least one component A and at least one component B, wherein component A has a binding activity for cellular surface structures, and component B carries a protease or derivatives thereof as an effector function. | 03-26-2009 |
20090081186 | METHODS AND COMPOSITIONS FOR PREVENTING AND/OR TREATING PANCREATITIS - The present invention relates to a method of preventing and/or treating pancreatitis in a subject, the method including administering to the subject a therapeutically effective amount of a Galanin antagonist and/or a Galanin receptor antagonist. | 03-26-2009 |
20090081187 | Pharmacological vitreolysis - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 03-26-2009 |
20090081188 | GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 03-26-2009 |
20090098102 | Cosmetic Composition Containing Enzyme and Amino Acid - The present invention relates to a skin cosmetic composition containing enzyme and amino acid. More particularly, the skin cosmetic composition according to the invention contains enzyme and amino acid, and thus safely improves stratum corneum thickening resulting from the progression of skin aging, improves skin drying occurring during keratin removal, and shows excellent skin moisturizing and whitening effects. | 04-16-2009 |
20090098103 | Modified factor VII polypeptides and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 04-16-2009 |
20090098104 | Method for Diagnosing Cardiovascular Diseases - Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual; determining the amount of cytokeratin-18 (CK-18) or fragments thereof and/or interleukin-1β precursor (IL-1β precursor) in said sample; comparing the amount of CK-18 or fragments thereof and/or IL-1β precursor in said sample to the amount of CK-18 or fragments thereof and/or IL-1β precursor present in a reference control of at least one individual not suffering from a cardiovascular disease; and diagnosing a cardiovascular disease if the amount of CK-18 or fragments thereof in the sample is increased in comparison to the amount of CK-18 or fragments thereof in the reference control and/or the amount of IL-1β precursor in the sample is decreased in comparison to the amount of IL-1β precursor in the reference control. | 04-16-2009 |
20090117093 | GRANULYSIN PEPTIDES AND METHODS OF USE THEREOF - Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions. | 05-07-2009 |
20090123452 | Protease screening methods and proteases identified thereby - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 05-14-2009 |
20090123453 | Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin - The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X obtained from plasma or by means of genetic engineering, which can be at least partially in the activated state, and coagulation factor X1a obtained from plasma or by means of genetic engineering, and (C) phospholipids which are safe from prions and contribute to the clotting process, said phospholipids being optionally contained in liposomes. | 05-14-2009 |
20090130085 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations - The invention relates to novel compounds of the formula (I) and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof. | 05-21-2009 |
20090130086 | FXIII Variants with Improved Properties - The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed. | 05-21-2009 |
20090130087 | METHOD FOR MEASURING THE CONTENT OF A BOTULINUM TOXIN IN A FORMULATION - A method of measuring the concentration of a bioactive agent is disclosed. | 05-21-2009 |
20090136477 | Methods of generating and screening for proteases with altered specificity - Disclosed herein are methods for generating proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using these proteases to treat diseases in which the target proteins are involved with. Cleaving certain target proteins at certain substrate sequences with a protease is a method for treating these pathologies. | 05-28-2009 |
20090142330 | Use of inactive-plasmin to treat chronic inflammatory disease and tumors - Methods are provided for the suppression of inflammation or a tumor. The methods can include selecting a subject in need of suppression of inflammation or the tumor and inhibiting plasmin activity in the subject to decrease matrix metalloproteinase production, thereby suppressing the inflammation or tumor. In several examples, an agent including inactive plasmin at a therapeutically effective concentration is administered to inhibit plasmin activity. Methods are also provided for modulating annexin A2 receptor activity. | 06-04-2009 |
20090155240 | DICHLOROACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS - The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical benefit. The present invention teaches administration of DCA with cardioprotective or hemodynamic drugs as an adjunct therapy thereby conferring added clinical benefit to clinically recommended protocols. | 06-18-2009 |
20090162342 | THERAPEUTIC USES OF GLANDULAR KALLIKREIN - The present invention relates to pharmaceutical compositions comprising glandular kallikrein in combination with myelin basic protein or copaxone for use in the treatment of multiple sclerosis. The present invention further relates to a method of suppressing autoimmune responses in a patient afflicted with or suffering at least one clinical sign of multiple sclerosis, comprising administering to said patient a therapeutically effective amount of glandular kallikrein in combination with a therapeutically effective amount of myelin basic protein or copaxone. | 06-25-2009 |
20090162343 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 06-25-2009 |
20090169539 | PDGF FUSION PROTEINS INCORPORATED INTO FIBRIN FOAMS - Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions are suitable for use in a method for forming a fibrin matrix or foam that can be applied or injected at the site of need. In another preferred aspect, the compositions are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices that can be administered as gels or foams. | 07-02-2009 |
20090181006 | METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES - Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and are directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room. | 07-16-2009 |
20090181007 | CULTURE MEDIUM AND PHARMACEUTICAL COMPOSITION FOR REGENERATING CARTILAGE TISSUE, A METHOD, USES AND PRODUCTS RELATED THERETO - A composition for in vitro use as a culture medium or in vivo use as a pharmaceutical composition or a medical device, capable of accelerating the differentiation of stem cells into cells with a chondrocytic phenotype and of restoring the original trophism of chondrocytes, is described. The composition comprises, in combination, at least one proteolytic enzyme, at least one growth factor and at least one from a sugar, an amino acid, a vitamin factor, a vitamin, a nucleotide and a nucleoside, in a physiologically acceptable carrier or diluent. A method of differentiating stem cells in cells having a chondrocytic phenotype, the cells obtained by the method and their uses, for example in human or animal cell therapy, for example by CBMP (Cellular Based Medicinal products) are also described. | 07-16-2009 |
20090186013 | INORGANIC MATERIALS FOR HEMOSTATIC MODULATION AND THERAPEUTIC WOUND HEALING - The invention provides compositions, methods and devices relating to a silaceous oxide that generates a reduced heat of hydration upon contact with blood. By reducing the heat of hydration, the compositions provide a hemostatic agent that attenuates a tissue burning side effect of conventional hemostatic agents without adversely affecting the wound healing properties of the composition. | 07-23-2009 |
20090191179 | Use of factor VIIa analogues with increased activity - The invention relates to methods for the treatment of a severely bleeding subject. | 07-30-2009 |
20090191180 | Use of Factor VIIa Analogues with Increased Activity - The invention relates to methods for treatment of bleeding episodes in a subject with thrombocytopenia. | 07-30-2009 |
20090196865 | Methods for the treatment and prevention of diseases of biological conduits - Methods for treating or preventing disease in biological conduits are provided herein. In certain embodiments, the methods relate to reducing or preventing vasospasm in blood vessel walls. In other embodiments, the methods described herein relate to reducing the accumulation of intimal hyperplasia in blood vessel walls after vascular procedures, including surgery. The methods encompass the use of agents that are useful for dilating biological conduits, but in dosages lower than are effective to achieve dilation of biological conduits. | 08-06-2009 |
20090208481 | Proteomic analysis of active multiple sclerosis lesions - The invention provides methods for treating demyelinating inflammatory diseases by administering to the subject an effective amount of an agent that provides activated protein C activity, where the dose is effective to reduce the adverse clinical indicia of the disease. In some embodiments, the patient being treating is of the chronic active plaque type. | 08-20-2009 |
20090220482 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist. | 09-03-2009 |
20090226412 | AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER - The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system. | 09-10-2009 |
20090232790 | Kit of Lyophilized Thrombin and Lyophilized Fibrinogen Used to Compound Fibrin Membrane, and Its Application - A kit of lyophilized thrombin and lyophilized fibrinogen comprises fibrinogen of 50-100 mg/ml, thrombin of 100-1000 IU/ml and 20-60 mmol/L CaCl | 09-17-2009 |
20090232791 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers. | 09-17-2009 |
20090246188 | Method for Production of a Bioengineered Form of Tissue Plasminogen Activator - The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of the endogenous tissue plasminogen activator asparagine has been replaced by glutamine, leading to the removal of an N linked glycosylation site. At position 296-299 the amino acids lysine, histidine, arginine, and arginine have been replaced by four alanine amino acids. The invention further relates to the de novo synthesis of the nucleic acid sequence encoding tissue plasminogen activator, transformation of the constructed nucleic acid sequences into competent bacteria and sub-cloning of the same into mammalian expression vectors for the expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest have been disclosed. The recombinant human tissue plasminogen activator, according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for treatment of treatment of heart attack and stroke patients. These compositions are yet another aspect of the present invention. | 10-01-2009 |
20090252720 | Prolonged FIX Analogues and Derivatives - The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue. | 10-08-2009 |
20090263374 | METHOD OF PREVENTING AND TREATING BRAIN INFARCTION - The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present invention relates to a method of preventing and treating cerebral infarction by activating PAR-2 and/or promoting expression of PAR-2 gene. The present invention further relates to a pharmaceutical composition for preventing and treating cerebral infarction, comprising one, or two or more of the active ingredients selected from the group consisting of a PAR-2 activator and/or a PAR-2 gene expression promoter; as well as a pharmaceutically acceptable carrier. It further relates to a method of screening an active ingredient for preventing and treating cerebral infarction using as an indicator the PAR-2 activation promoted by a test substance. | 10-22-2009 |
20090280107 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 11-12-2009 |
20090297498 | Milk Fat Globule Epidermal Growth Factor-Factor VIII And Sepsis - Provided are methods of treating a mammal undergoing sepsis or at risk for sepsis. Also provided are methods of preventing or treating a physiologic effect of sepsis in a mammal. Additionally provided is the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal, and the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the treatment of a mammal having sepsis or at risk for sepsis. | 12-03-2009 |
20090304669 | PREPARATIVE PURIFICATION PROCESS FOR HUMAN FURIN - Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%. | 12-10-2009 |
20090304670 | FOOD PRODUCT COMPRISING A PROLINE SPECIFIC PROTEASE, THE PREPARATION THEREOF AND ITS USE FOR DEGRADING TOXIC OR ALLERGENIC GLUTEN PEPTIDES - The present invention relates to a pasteurized food product having a water activity of at least 0.80, preferably at least 0.85 and containing a proline specific protease. | 12-10-2009 |
20090304671 | Method of treating endothelial dysfunction - Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders. | 12-10-2009 |
20090311239 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII | 12-17-2009 |
20090311240 | VEGF165 Delivered by Fibrin Sealant to Reduce Tissue Necrosis - The present application demonstrates the clinical potential of fibrin sealants to locally deliver growth factors to ischemic tissue. More particularly, it demonstrates that hydrogels such as Fibrin Sealants can be used to deliver VEGF | 12-17-2009 |
20100008898 | CHYMOTRYPSIN FROM LUCILIA SERICATA LARVAE AND ITS USE FOR THE TREATMENT OF WOUNDS - The use of larval enzymes, particularly a chymotrypsin, is described herein. The enzymes are usable in the treatment of wounds for debridement and for cell regeneration. | 01-14-2010 |
20100008899 | METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS - The invention relates to pharmaceutical compositions comprising tissue kallikrem (TK), and optionally a diabetes drug, a method of screening for a metabolic disorder by determining the concentration of TK and insulin in a biological sample from a test subject, a method of screening for a therapeutic agent for the treatment or prevention of a metabolic disorder, and a method for treating or preventing a metabolic disorder using a pharmaceutical composition comprising TK. | 01-14-2010 |
20100015123 | NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR - New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes. | 01-21-2010 |
20100034803 | ACTIVATING AGENT OF STEM CELLS AND/OR PROGENITOR CELLS - The present invention provides an activating agent of stem cells and/or progenitor cells comprising a thrombin-like enzyme which can be used in regenerative medicine, and particularly in regenerative medicine utilizing self-regeneration, acting promptly and moderately depending on the state of advancement and the degree of injured organs and/or tissues to which regenerative medicine is applied, with few or no side effects. The present invention also provides a method for activating stem cells and/or progenitor cells in an animal comprising the step of administering to the animal an effective amount of a thrombin-like enzyme and use of the thrombin-like enzyme for activating stem cells and/or progenitor cells. | 02-11-2010 |
20100034804 | MUTANTS OF STREPTOKINASE AND THEIR COVALENTLY MODIFIED FORMS - The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants. | 02-11-2010 |
20100040597 | THROMBIN MUTANT - A thrombin mutant in which at least serine at position 205 among amino acids in the active center of the thrombin B chain has been replaced with another amino acid, and further at least one of the following replacements have been introduced: (I) replacement of arginine at position 89 in the B-chain with another amino acid; (II) replacement of threonine at position 69 or serine at position 22 in the B-chain with another amino acid; (III) replacement of alanine at position 200 in the B-chain with another amino acid; and (IV) replacement of lysine at position 65 in the B-chain with threonine. | 02-18-2010 |
20100047228 | RECOMBINANTLY MODIFIED PLASMIN - Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme. | 02-25-2010 |
20100047229 | PURIFIED RECOMBINANT BATROXOBIN WITH HIGH SPECIFIC ACTIVITY - A purified recombinant batroxobin with high specific activity, which has the following properties: (a) the batroxobin has a molecular weight of 29-32 kDa; (b) at least 90% of the batroxobin have 6 pairs of disulfide bonds which correctly match at Cys | 02-25-2010 |
20100055087 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist. | 03-04-2010 |
20100068196 | METHOD OF MICRONIZATION - A method for micronization of a dispersion of particles including a protein having a predetermined level of biological activity, is provided. The method includes introducing the dispersion into a vortex chamber milling apparatus under milling conditions which result in a protein powder having a particle size distribution of 5 to 100 μm and/or exhibiting a 30 to 400 fold size reduction of the protein particle dispersion from its original size, and retaining at least 80% of the predetermined level of biological activity of the protein. The milling conditions include one or more parameters selected from the following: input pressure between 1 and 7 Bars; injector pressure between 0.2 and 5 Bars; loading rate between 0.1 and 5 kg/hour; and gas flow between 30 and 100 m | 03-18-2010 |
20100080791 | Composition and Method For Treating Tissue Defects - The present invention provides a composition and method for treating tissue defects. The composition includes thrombin and fibrinogen, or sodium alginate and calcium chloride, and also a surfactant, and non-resorbable polymer microparticles dispersed within the composition. | 04-01-2010 |
20100086536 | Method of Increasing Plasmin Activity through Antiplasmin Conversion - Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the patient. Also provided are methods for the identification of compounds or molecules that increase plasmin activity, comprising determining whether the compound or molecule binds to a binding site on α2-antiplasmin which increases the conversion of α2-antiplasmin from an inhibitor to a plasmin substrate, wherein the compound or molecule is not an antibody, thereby identifying a compound or molecule which increases plasmin activity. Further provided are pharmaceutical compositions and methods of use thereof for the treatment of myocardial infarction, thrombosis, ischemic stroke, and pulmonary embolism. | 04-08-2010 |
20100092453 | Method of producing porous microparticles - A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile solvent system, and spray drying the system thus formed to provide porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof. | 04-15-2010 |
20100104550 | CLEAVAGE OF BIP BY SUBTILASE CYTOTOXIN - Cleavage of BIP (Immunoglobulin binding protein) by subtilase toxin and its application to inhibiting growth of or killing of cells. This has application to treatment of cancers and to conformational diseases and in particular to conformational diseases involving BiP that are influenced by cleavage by the subtilase cytotoxin. The invention also relates to subtilase toxin molecules specifically targeting proliferating cells, in particular tumor cells, or cells expressing a vascular endothelial growth factor receptor. | 04-29-2010 |
20100104551 | METHOD FOR PROLONGING ACTIVITY OF AUTODEGRADABLE ENZYMES AND COMPOSITIONS THEREOF - A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment. | 04-29-2010 |
20100111926 | Method of Using Salmon Thrombin to Alleviate Central Nervous System-Mediated Pain - A method of alleviating central nervous system-mediated pain includes applying salmon thrombin at a neural injury site. Applying salmon thrombin can include applying a gel that includes salmon thrombin. The gel can also include fibrinogen, for example, salmon fibrinogen, human fibrinogen, or bovine fibrinogen. The salmon thrombin can be obtained from salmon plasma, or using recombinant technology, or by fractionation. A pain relief substance includes a gel that includes salmon thrombin. | 05-06-2010 |
20100143325 | Composition And Methods Involving Thrombolytic Agents - Treatment or prevention methods are described wherein t-PA and C1-inhibtor are used together in order to minimize the hemorrhagic complications of tPA Preferably, C1-inhibitor is infused prior to treatment with t-PA, thereby allowing for a safer thrombolysis without the excessive and dangerous bleeding associated with the use of t-PA alone particularly in the treatment of ischemic stroke. | 06-10-2010 |
20100143326 | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES - The invention relates to the use of a Factor VIIa-related polypeptide for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, in particular a bleeding episode, said medicament being for subcataneous or intramuscular administration. | 06-10-2010 |
20100143327 | Injection of fibrin sealant including an anesthetic in spinal applications - A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises an anesthetic, fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc. | 06-10-2010 |
20100150899 | PYRAZOLINONE SCAVENGERS OF FREE RADICAL - The present invention relates to new pyrazolinone scavengers of free radicals, pharmaceutical compositions thereof, and methods of use thereof. | 06-17-2010 |
20100150900 | Dry Powder Fibrin Sealant - The invention provides a composition comprising a mixture of first microparticles that comprise fibrinogen and trehalose, and second microparticles that comprise thrombin and trehalose. The invention further provides methods for treating wounds by administering the novel microparticle composition. | 06-17-2010 |
20100158890 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 06-24-2010 |
20100158891 | Human Coagulation Factor VII Variants - The present invention encompasses isolated human coagulation Factor VII variants comprising a substitution of Phe in position 374 of SEQ ID NO 1 with another amino acid residue. | 06-24-2010 |
20100166729 | Modified factor VII polypeptides and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 07-01-2010 |
20100166730 | Liquid, Aqueous Pharmaceutical Composition of Factor VII Polypeptides - The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and/or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv). | 07-01-2010 |
20100178287 | USE OF COAGULATION PROTEINS TO LYSE CLOTS - The present invention relates to the use of coagulation proteins for the lysis of blood clots. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X, Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject. | 07-15-2010 |
20100183582 | HEMOSTATIC COMPOSITIONS CONTAINING STERILE THROMBIN - The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the continuous liquid phase, and methods for making such compositions. | 07-22-2010 |
20100189709 | ELASTASE INHIBITOR - An elastase inhibitor containing, as an active ingredient, a protein hydrolysate (with soybean protein hydrolysate and almond protein hydrolysate being excluded). Pharmaceuticals and cosmetics containing such an elastase inhibitor which exhibit an inhibitory effect against the growth of body hair, and skin aging preventing effect by restoring elasticity and tonicity of the skin and reducing wrinkles. | 07-29-2010 |
20100196348 | COMBINATION TREATMENT WITH t-PA VARIANT AND LOW MOLECULAR WEIGHT HEPARIN - The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin. | 08-05-2010 |
20100203034 | METHODS FOR THE TREATMENT AND PREVENTION OF DISEASES OF BIOLOGICAL CONDUITS - Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall of the conduit or by inflammatory cells that are attracted to the conduit, thereby providing additional conduit dilation. Methods also include the use of agents that increase conduit wall permeability and expose elastin and collagen fibers. Methods also include removing components of the extracellular matrix of arteries and veins leading to an inhibition of intimal hyperplasia in the wall of the vessels by decreasing biomechanical stimuli directed toward the cells in the wall of the vessel. Methods further include the use of agent that degrade microfibers, in addition to elastin, in order to decrease the resynthesis of elastin. Methods also include the use of agent that stabilize the diameter of aneurysmal arteries by blocking cell surface receptors in the wall of the aneurysmal artery that are important in the recruitment of inflammatory cells. | 08-12-2010 |
20100209413 | SERPINE1 POLYMORPHISMS ARE PREDICTIVE OF RESPONSE TO ACTIVATED PROTEIN C ADMINISTRATION AND RISK OF DEATH - Methods, oligonucleotides arrays etc. for treating inflammatory conditions and of predicting subject outcome based on polymorphisms in SERPINE1 and/or PROC, alone or in combination, wherein the method of treatment includes administering to the subject an anti-inflammatory agent or an anti-coagulant agent, wherein said subject is determined to have an improved response genotype or combination. | 08-19-2010 |
20100215636 | PEPTIDES DERIVED FROM PLASMINOGEN ACTIVATOR INHIBITOR-1 AND USES THEREOF - The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage. | 08-26-2010 |
20100226910 | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN - This invention relates to methods of treating Alzheimer's disease or symptoms thereof, and amnesic mild cognitive impairment or symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to uses of tissue kallikrein or a variant or active fragment thereof for the digesting or cleaving amyloid and the treatment of conditions benefiting from the digestion or cleavage of amyloid. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration. | 09-09-2010 |
20100233147 | METHOD AND APPARATUS FOR THROMBUS REMOVAL USING MAGNETIC PARTICLES - A method and system for affecting a thrombus after ischemic stroke. The method may include injecting a plurality of magnetic particles into a bloodstream and moving or distorting a thrombus formed or lodged in the bloodstream using a magnetic force to manipulate the magnetic particles. The method may include conjugating ferromagnetic particles, paramagnetic particles, or superparamagnetic particles to a thrombus-specific attachment agent such as an anti-fibrin antibody, and injecting the conjugated particles into the bloodstream. Thereafter, the thrombus may be agitated, broken apart, or dissolved using a magnetic field to exert a magnetic force on the conjugated particles. The method may also include injecting a thrombolytic agent into the bloodstream to interact with and further dissolve the thrombus. | 09-16-2010 |
20100233148 | Injection of fibrin sealant including an anesthetic in spinal applications - A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises an anesthetic, fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc. | 09-16-2010 |
20100233149 | Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same - Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate. | 09-16-2010 |
20100239560 | MULTI COMPONENT NON-WOVEN - The formation of a non-woven, free from organic solvent, formed through parallel formation of fibers on a collection device is disclosed. As the individual fibers are dry prior to contact with other fibers, the different contents of the various fiber types do not interact. However, when wetted, the fibers will start to be dissolved, or swell, and the different contents will be released and then interact. For the example of thrombin and fibrinogen, the interaction will initiate the formation of a fibrin coagulum by the cleavage of fibrinogen through the action of thrombin to form fibrin monomers that spontaneously polymerize to form a three dimensional network of fibrin. | 09-23-2010 |
20100247510 | AGENT FOR REDUCING A SIDE EFFECT OF AN ANTICANCER DRUG - The present invention provides an agent for reducing a side effect of an anticancer drug, which comprises a thrombin-like enzyme. | 09-30-2010 |
20100247511 | METHODS AND COMPOSITIONS FOR ACTIVATED PROTEIN C WITH REDUCED ANTICOAGULANT PROPERTIES - This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding. | 09-30-2010 |
20100254968 | PHARMACEUTICAL PREPARATION FOR TREATING BENIGN PROSTATIC HYPERPLASIA - The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of benign prostate hypertrophy/hyperplasia, wherein the medicament is adapted for enteral administration, the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases and the at least one protease is administered in an amount of 1 to 100 mg/kg body weight. | 10-07-2010 |
20100260741 | Factor VII or VIIa Polypeptide Variants - The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma. | 10-14-2010 |
20100266572 | TREATMENT AND PREVENTION OF ISCHEMIC INJURY USING ACTIVATED PROTEIN C - Methods and compositions are provided for treating or preventing ischemic injury in a tissue flap in order to reduce the incidence of flap necrosis. Some compositions comprise one or more of an activated protein C (APC), a functional fragment of an APC, an APC mimetic compound, and a derivative of APC. Some methods comprise administering to a subject a therapeutically effective amount of an agent comprising one or more of an activated protein C (APC), a functional fragment of an APC, an APC mimetic compound, and a derivative of APC. | 10-21-2010 |
20100272704 | NOVEL PATIENT SUBGROUPS FOR THROMBOLYSIS - A method for treating a stroke patient with thrombolysis, wherein prior to treatment the patient is diagnosed in particular for exhibiting cerebral tissue at risk, a cerebral artery occlusion, and/or an absolute “mismatch volume”. | 10-28-2010 |
20100284997 | DOSING REGIMEN OF ACTIVATED PROTEIN C AND VARIANTS HAVING REDUCED ANTICOAGULANT ACTIVITY - Recombinant activated protein C (APC) and APC variants with reduced anticoagulant activity were used to reduce mortality in murine models of sepsis. These models included endotoxemia and bacteremia models. We discovered that single or multiple bolus doses of APC, especially of APC variants such as RR230/231AA-APC, KKK192-194AAA-APC and 5A-APC (containing the combination of mutations present in the first two APC variants) given as a single bolus reduces 7-day mortality of mice given lethal doses of endotoxin. Administrations of a single bolus of 5A-APC after the initiation of sepsis also reduces mortality caused by LPS. 5A-APC with ≦8% of normal anticoagulant activity (which has reduced risk of bleeding) reduces mortality when given as two bolus administrations at 3 hours and then at 10 hours after initiation of bacterial infection, i.e. after onset of sepsis. This shows, first, that one or more bolus injections of APC or of APC variants, especially 5A-APC, can reduce mortality when given beginning hours after the onset of sepsis and, second, that it is not necessary to administer APC as a continuous infusion which is the current standard of practice because one or more bolus administrations can reduce mortality. Furthermore, dosages of approximately 0.06 to 0.4 mg/kg of APC and APC variants are identified to be sufficient to reduce mortality in sepsis. | 11-11-2010 |
20100284998 | FIBRIN SEALANT - A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application. | 11-11-2010 |
20100297099 | Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract - The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of human activated protein C or biologically active derivatives thereof. | 11-25-2010 |
20100297100 | Composition for Treating Retinopathy or Glaucoma Comprising Thrombin Derived Peptides - Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component. | 11-25-2010 |
20100303799 | Treatment of Conditions Related to Shock - Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques. | 12-02-2010 |
20100303800 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIA - A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2. | 12-02-2010 |
20100316625 | STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE - Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20° C. and 2-8° C. | 12-16-2010 |
20100322918 | Diffusion enhancing compounds and their use alone or with thrombolytics - The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke. | 12-23-2010 |
20100330063 | STEM-LIKE CELLS, METHOD FOR DE-DIFFERENTIATING MAMMALIAN SOMATIC CELLS INTO STEM-LIKE CELLS, AND METHOD FOR DIFFERENTIATING STEM-LIKE CELLS - A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from embryos or fetuses, and without the need of potentially harmful transfecting vectors. Stem-like cells created by the present invention can be induced to differentiate into terminally differentiated adult somatic cells, such as, for example, neuronal cells. | 12-30-2010 |
20100330064 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 12-30-2010 |
20110002910 | THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS - The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax. | 01-06-2011 |
20110008315 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 01-13-2011 |
20110008316 | Biological bioadhesive compositions and methods of preparation and use - The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the presence of biological and/or non-biological agents such as drugs, chemicals, and proteins. Preferably, these agents are introduced in solution, such as for example, a corticosteroid-containing solution like a betamethasone solution containing betamethasone acetate or betamethasone sodium phosphate; a triamicinolone solution; or a methylprednisolone solution. These solutions may be substituted for, or provided as a complement to, other solutions that are typically used in the preparation of fibrin sealants such as, for example, calcium chloride. The invention further relates to a novel method of using the improved fibrin sealant whereby the sealant and accompanying agent(s) are delivered directly to a critical site within the body and sealed in place due to the bio-static quality of the sealant. This provides therapeutic value to patients through prolonged presence, and optionally time-released delivery, of the specific agent(s) at the critical site. | 01-13-2011 |
20110014179 | USE OF FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN A SELECTED SUBPOPULATION OF ICH PATIENTS - The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age≦70, baseline ICH volume≦60 mL, baseline IVH volume≦5 mL, and elapsed time since onset of symptoms of less than about 2.5 hours; and (ii) administering to said patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent. | 01-20-2011 |
20110027257 | CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND PREPARATION METHOD THEREOF - The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGT-β, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating the platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and/or the detergent by oil extraction and/or chromatographic means. | 02-03-2011 |
20110027258 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 02-03-2011 |
20110038847 | PROCESS FOR PREPARING BIOABSORBABLE SHEET PREPARATION HOLDING THROMBIN - A process for preparing a bioabsorbable sheet preparation holding thrombin is provided. A process for preparing a bioabsorbable sheet preparation holding thrombin which comprises immersing a bioabsorbable sheet consisting of polyglycolic acid in a thrombin solution containing thrombin as an active ingredient, glycerol as a softening agent, Tween 80 as a permeating agent, and optionally histidine and trehalose as a stabilizing agent followed by drying to hold thrombin on said bioabsorbable sheet, and a bioabsorbable sheet preparation holding thrombin prepared by said process. | 02-17-2011 |
20110044970 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DRY EYE - The invention generally relates to methods and compositions for treating dry eye and related conditions by administering compositions comprising compounds that increase capillary permeability of either the lacrimal gland, accessory lacrimal gland, or ocular surface. | 02-24-2011 |
20110052561 | OSTEOLYSIS TREATMENT - Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist includes using an implantable device loaded with adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells. Methods for treating osteolysis at the site of an artificial joint in a patient include administering and/or inserting the solution rich in interleukin-1 receptor antagonist and/or the implantable device, respectively. | 03-03-2011 |
20110052562 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R | 03-03-2011 |
20110064719 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY PURIFICATION OF FACTOR VII POLYPEPTIDES - The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern. | 03-17-2011 |
20110076261 | Antifungal Drug Delivery System - A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent having a pH−pKa value of 0.5 or more formulated into shampoos, creams, lotions, gels, sprays, foams, pads, films, patches, and solutions for treatment of skin disorders and diseases in both humans and animals. | 03-31-2011 |
20110081334 | C1-Inhibitor Prevents Non-Specific Plasminogen Activation by a Prourokinase Mutant without Impeding Fibrin-Specific Fibrinolysis - A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis. Methods of reducing bleeding and non-specific plasminogen activation during fibrinolysis by administering M5 along with exogenous C1-inhibitor are disclosed. | 04-07-2011 |
20110091443 | HEPARIN-CONJUGATED FIBRIN GEL AND METHOD AND KIT FOR PREPARING SAME - A method of preparing a heparin-conjugated fibrin gel is provided, which includes activating heparin, conjugating the activated heparin with fibrinogen to prepare heparin-conjugated fibrinogen, mixing free fibrinogen with the heparin-conjugated fibrinogen to prepare a fibrinogen mixture, and mixing thrombin with the fibrinogen mixture. In addition, a heparin-conjugated fibrin gel prepared by the above method and a kit for preparing the same are provided. According to the method of preparing the heparin-conjugated fibrin gel, the heparin-conjugated fibrin gel having an affinity for drugs such as growth factors may be easily prepared at low costs, and can also be used as a therapeutic drug excellently effective on generation of tissues such as bones, skin, blood vessels, cartilages, etc. by sustainably releasing drugs such as growth factors to a local site for a long period of time through injection into a human body. | 04-21-2011 |
20110104142 | FORMULATIONS OF PEG-FUNCTIONALISED SERINE PROTEASES WITH HIGH CONCENTRATIONS OF AN AROMATIC PRESERVATIVE - The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i) functionalised with one or more polyethylene glycol (PEG) moieties, said PEG moieties having a molecular weight of at least 300 Da; a buffering agent (ii) suitable for keeping pH in the range of from about 5.0 to about 9.0; and at least one aromatic preservative (iii) in a concentration of at least 0.1 mg/mL. | 05-05-2011 |
20110110920 | METHOD OF TREATING PERIPHERAL ARTERIAL DISEASE - An agonist of a non-proteolytically activated thrombin receptor can be used in a method for treating peripheral arterial disease. The agonist can be a thrombin peptide derivative. In some embodiments, the peripheral arterial disease is characterized by intermittent claudication. The thrombin peptide derivatives to be used in the methods can have amino acid sequences similar to a region of thrombin. Usually, the thrombin peptide derivatives are 12-23 amino acid residues in length. In some cases, the thrombin peptide derivatives are dimers, and in particular, dimers that result from formation of a disulfide bond between two cysteine residues of peptide monomers. | 05-12-2011 |
20110110921 | Methods for Treating Bleeding Disorders - A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor XI; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor XI-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI. | 05-12-2011 |
20110117075 | THROMBIN DERIVED PEPTIDES FOR SMOOTH MUSCLE RELAXATION - Agonists of a non-proteolytically activated thrombin receptor, and more particularly, thrombin peptide derivatives, can be used in methods to cause smooth muscle relaxation. Compositions comprising thrombin peptide derivatives can be administered to a subject with a disease or disorder that can be ameliorated by relaxation of smooth muscle. Such compositions can also be administered to a subject to facilitate medical, diagnostic or surgical procedures. | 05-19-2011 |
20110123517 | DISSOLVABLE PHARMACEUTICAL IMPLANT - A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device. | 05-26-2011 |
20110142819 | METHOD OF IMPROVING WOULD HEALING - This invention relates to novel methods of promoting the healing or closure of perforated tympanic membranes or wounds, as well as methods for minimizing scar formation and removing necrotic tissue. In particular the invention relates to the use of components of the plasminogen activating system, especially mini-plasminogen, mini-plasmin, micro-plasminogen, micro-plasmin, delta-plasminogen, and delta-plasmintopromote wound healing processes. | 06-16-2011 |
20110165142 | METHOD OF TREATING DEGENERATIVE DISEASES - Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy. | 07-07-2011 |
20110171199 | METHOD FOR REDUCING OR ELIMINATING PAIN ASSOCIATED WITH A POST-OPERATIVE WOUND - The present invention relates to methods for ameliorating or preventing pain associated with a post-operative wound and kits related thereto. The method comprises administering to the wound an effective amount of an anti-clotting agent solution and administration of an effective amount of an analgesic mixture solution comprising a fast-acting analgesic and a slower-acting analgesic. | 07-14-2011 |
20110171200 | PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND - Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rs1799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. Also provided are methods of treating subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype. | 07-14-2011 |
20110182876 | Methods of Treatment with Elastase - The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 07-28-2011 |
20110189160 | Veterinary Topical Agent - Methods and compositions for treating skin conditions in animals, which tend to have higher skin pH than humans, including wounds, ulcers, rashes, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates the use of an aqueous or emollient medium having non-occlusive properties with one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface. | 08-04-2011 |
20110200577 | BIOMATRICES TO ATTRACT AND RETAIN REGENERATIVE AND REPARATIVE CELLS - The invention relates to a pharmaceutical composition which comprises a fibrin clot and a cytokine and methods of delivering the composition to a site of disease or injury in vivo to attract and retain regenerative or reparative stem or myeloid cells and their differentiated progeny. | 08-18-2011 |
20110200578 | INTRAVENTRICULAR HEMORRHAGE THROMBOSIS - The invention provides methods of treating intraventricular hemorrhage using thrombolytic agents. | 08-18-2011 |
20110206655 | FVIII-INDEPENDENT FIX-MUTANT PROTEINS FOR HEMOPHILIA A TREATMENT - The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors. Therefore these FIX mutants are alternatives as bypassing agents for treatment of FVIII inhibitor patients. | 08-25-2011 |
20110212075 | SCREENING METHOD FOR POLYMORPHIC MARKERS IN HTRA1 GENE IN NEURODEGENERATIVE DISORDERS - The invention relates to a method of screening a subject for at least one risk factor associated with a neurodegenerative disease such as Alzheimer's disease comprising detecting the presence or absence of at least one risk marker in the HtrA1 gene (PRSS11). Furthermore, diagnostic kits as well as therapeutic approaches are provided. | 09-01-2011 |
20110217284 | Factor IX Variants with Clotting Activity in Absence of Their Cofactor and Their Use for Treating Bleeding Disorders - The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications. | 09-08-2011 |
20110217285 | KERATIN BIOMATERIALS FOR TREATMENT OF ISCHEMIA - Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns. | 09-08-2011 |
20110223150 | Neutraceutical-Based Topical Anxiolytic Agent and Method of Use - A nutraceutical-based anxiolytic agent (composition) for topical application is described. The formulation utilizes a combination of active ingredients directed to up-regulate the parasympathetic nervous system and calming vagal nerve enervation and its resultant stress symptomatology. The active ingredients in the topical composition include GABA (gamma-aminobutyric acid), L-theanine, Phenibut (beta-phenyl-gamma-aminobutyric acid), and casein tryptic hydrolysase. The active ingredients are dissolved in a lecithin organogel carrier such as Lipoderm or Phloderm to provide a superior transdermal delivery system. | 09-15-2011 |
20110223151 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY - The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia. | 09-15-2011 |
20110229453 | BLOOD COAGULATION FACTOR INHIBITORS - The invention relates to novel compounds with formula (I) useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIa, Factor VII variants, or Factor VII derivatives. | 09-22-2011 |
20110229454 | Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction - In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI. | 09-22-2011 |
20110243917 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF ABSENCE SEIZURES COMPRISING PKC AGONIST AS AN EFFECTIVE INGREDIENT - The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food. | 10-06-2011 |
20110262424 | RECOMBINANTLY PRODUCED HUMAN FACTOR VIII AND IX - A recombinant human factor VIII or IX protein having a human glycosylation pattern but the protein is devoid of N-glycolylneuraminic acid and/or the carbohydrate group Galα-3Gal. | 10-27-2011 |
20110280857 | ADVANCED FUNCTIONAL BIOCOMPATIBLE FOAM USED AS A HEMOSTATIC AGENT FOR COMPRESSIBLE AND NON-COMPRESSIBLE ACUTE WOUNDS - A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood. | 11-17-2011 |
20110280858 | TREATMENT OF WOUNDS - The invention generally provides compositions, kits, pharmaceuticals, and methods that promote and enhance wound healing. Such compositions comprise isolated trypsinogen or trypsin polypeptides or isolated polypeptides obtainable from the excretions/secretions (ES) of | 11-17-2011 |
20110280859 | PREVENTING AND TREATING SEPSIS - Provided are polypeptides comprising a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids. Also provided are methods of treating sepsis in a subject comprising administering to the subject one or more of the provided polypeptides or nucleic acids. Methods of screening for polypeptides with enhanced activated protein C and for an agent for treatment of sepsis are provided. Finally, provided is a method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides. | 11-17-2011 |
20110293597 | SERINE PROTEASE DERIVATIVES AND USES IN THE PREVENTION OR THE TREATMENT OF BLOOD COAGULATION DISORDERS - The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders. | 12-01-2011 |
20110300122 | METHOD FOR TREATING A PATIENT - Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor. | 12-08-2011 |
20110300123 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 12-08-2011 |
20110311510 | Compositions and methods for prion decontamination - The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents. | 12-22-2011 |
20110318330 | MEDICINAL PRODUCTS FOR THE TREATMENT OF BLOOD COAGULATION DISORDERS - A virally safe, thrombin-free factor-Xla concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation. | 12-29-2011 |
20120003206 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z | 01-05-2012 |
20120009174 | BIOMARKERS FOR MYOCARDIAL ISCHEMIA - This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention. | 01-12-2012 |
20120009175 | Method of Using Salmon Thrombin to Alleviate Pain - A method of alleviating pain associated with tissue damage includes applying salmon thrombin at a tissue damage site, as a single substance in liquid form, or as a powder, a foam, and/or a gel that includes salmon thrombin. A pain relief substance includes a salmon thrombin preparation. | 01-12-2012 |
20120014939 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF HAEMORRHAGIC CONVERSION - The invention provides a method for predicting a hemorrhagic disorder in a patient consisting determining amine oxidase and, particularly, VAP-1 in a sample from said patient. The invention also provides pharmaceutical compositions comprising an inhibitor of amine oxidase and an antithrombotic agent as well as the use of an inhibitor of amine oxidase for treatment of hemorrhagic disorders. | 01-19-2012 |
20120020948 | DAG-TYPE AND INDIRECT PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE - The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke. | 01-26-2012 |
20120027746 | METHOD FOR GENERATING THROMBIN - Methods of generating thrombin and methods of applying a clotting tissue sealant to a site on a subject are provided. A blood component comprising platelets can be obtained from the subject. A hypotonic composition is contacted with a solid matrix to form a thrombin-containing liquid, where the hypotonic composition includes water, calcium, a blood component comprising platelets, and optionally a chelator. Calcium is present in the hypotonic composition in an amount greater than the amount of calcium that can be complexed by the chelator. Thrombin-containing liquid is then separated from the hypotonic composition and can be applied to the site on the subject to form a clot, for example, by combination with fibrinogen. | 02-02-2012 |
20120034205 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE - The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | 02-09-2012 |
20120039862 | Extended Length Botulinum Toxin Formulation for Human or Mammalian Use - An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed. | 02-16-2012 |
20120039863 | RECOMBINANT FACTOR X WITH NO GLYCOSYLATION AND METHOD FOR PREPARING THE SAME - A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method. | 02-16-2012 |
20120045426 | COMPOSITIONS FOR REDUCING THE DELETERIOUS EFFECTS OF STRESS AND AGING - The invention provides a formulation for treating stress and lessening fatigue. The formulation can be combined with water or another suitable liquid to provide a beverage for ease of administration. The formulation can include one or more of an energy compound, a vasodilator, a vasodilator adjuvant, and an antioxidant enhancer. In a typical formulation the energy compound is D-ribose or guanosine. The formulation can improve energy and alertness, and reduce the effects of stress and fatigue. | 02-23-2012 |
20120070425 | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC Beta-CELL DYSFUNCTION AND FOR Beta-CELL PROLIFERATION - The invention relates to methods of administering kallikrein, a variant, or active fragment thereof to stimulate proliferation of islet cells generally and β-cells specifically. The invention also includes compositions to stimulate proliferation in vivo and in vitro. | 03-22-2012 |
20120087905 | TREATMENT OF DISEASES RELATED TO HYPERACTIVITY OF THE COMPLEMENT SYSTEM - Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described. | 04-12-2012 |
20120087906 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 04-12-2012 |
20120087907 | PROTHROMBIC COMPLEX COMPOSITION - The present disclosure relates to a method for preparing a composition or a concentrate of a prothrombic complex that includes the II, VII, IX and X coagulation factors, including providing a supernatant of a plasma cryoprecipitate, applying the supernatant on an anion-exchange resin for producing an eluate containing the complex and proteins having a high molecular weight, and applying the eluate on a hydroxyapatite column for producing a second eluate containing the complex. The disclosure also relates to a composition that can be produced by the method. | 04-12-2012 |
20120087908 | FACTOR VII COMPOSITION - The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant. | 04-12-2012 |
20120093798 | Methods for Treatment of Stroke or Cerebrovascular - Methods of using an ET | 04-19-2012 |
20120093799 | RECOMBINANTLY MODIFIED PLASMIN - Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme | 04-19-2012 |
20120114630 | VARIANTS OF PLASMINOGEN AND PLASMIN - The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed. | 05-10-2012 |
20120128653 | PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS - Described is a process for making a dry and stable hemostatic composition, said process comprising
| 05-24-2012 |
20120128654 | Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma - Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression of neurodegenerative diseases and for the treatment of neurotrauma-induced damage and cerebrovascular disease. | 05-24-2012 |
20120134980 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 05-31-2012 |
20120156187 | METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER - Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist. | 06-21-2012 |
20120164128 | MEANS AND METHODS FOR COUNTERACTING POLYQ EXPANSION DISORDERS - The present invention provides means and methods for counteracting and/or preventing aggregation of a polyQ protein. Further provided are improved poly constructs which are, amongst other things, useful for testing assays. According to the invention, several peptidases like, e.g. tripeptidyl peptidase II (TPPII), appear to be capable of cleaving long polyQ peptides comprising at least 45 glutamine residues. Hence, according to the invention, administration of such peptidases to an individual suffering from a polyQ expansion disorder results in degradation of long polyQ peptides. | 06-28-2012 |
20120164129 | EXPRESSION OF THROMBIN VARIANTS - One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition. | 06-28-2012 |
20120164130 | Modified Factor IX Polypeptides and Uses Thereof - The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more amino acid substitutions. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B. | 06-28-2012 |
20120177630 | TREATMENT OF RETT SYNDROME AND OTHER DISORDERS - The invention relates to methods for treatment of Rett Syndrome and other disorders of synaptic function and maturation using IGF1, (1-3)IGF-1, (1-3)IGF-1 analog(s) and/or related therapeutic molecules. | 07-12-2012 |
20120189609 | IMPROVEMENT TO TRABECULECTOMY - The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these. | 07-26-2012 |
20120201804 | TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER - The invention includes methods of treating psychiatric disorders including schizophrenia, associated conditions of the schizophrenic spectrum and bipolar disorder, comprising administering tissue kallikrein (KLK1), variants or active fragments thereof. The invention also includes compositions comprising KLK1, variants, or active fragments thereof. | 08-09-2012 |
20120225050 | METHODS FOR IMPROVING GUT HEALTH - The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of | 09-06-2012 |
20120225051 | TISSUE KALLIKREIN FOR THE TREATMENT OF HUNTINGTON'S DISEASE - This invention relates to methods of treating the prodrome and adult onset stage of Huntington's disease or symptoms thereof, and or Juvenile Huntington's disease symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration. | 09-06-2012 |
20120225052 | COMPOSITION AND METHOD FOR TREATING TISSUE DEFECTS - The present invention provides a composition and method for treating tissue defects. The composition includes thrombin and fibrinogen, or sodium alginate and calcium chloride, and also a surfactant, and non-resorbable polymer microparticles dispersed within the composition. | 09-06-2012 |
20120230977 | FLOWABLE COLLAGEN-BASED HEMOSTAT AND METHODS OF USE - The invention relates to hemostatic compositions and methods for promoting hemostasis. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents. | 09-13-2012 |
20120258090 | METHOD FOR PRODUCTION OF RECOMBINANT HUMAN THROMBIN - The present invention relates to a method is provided for producing recombinant human thrombin from recombinant prothrombin using recombinant ecarin having the sequence SEQ ID NO 2 or a homologue thereof. | 10-11-2012 |
20120263703 | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor DC coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions. | 10-18-2012 |
20120276079 | METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS - Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia. | 11-01-2012 |
20120276080 | SHEET-LIKE COMPOSITION - A sheet-shaped composition is provided which has an improved preservability and handling readiness, as well as a high flexibility in use. Amnion with trehalose added thereto is utilized. Addition of trehalose improves the flexibility of the amnion, and prevents basal membrane and stratum compactum from being damaged during lyophilization process. | 11-01-2012 |
20120282240 | THROMBIN ISOLATED FROM BLOOD AND BLOOD FRACTIONS - Methods, apparatus, and compositions related to generating and using thrombin. Methods include preparing a solution comprising thrombin by precipitating fibrinogen from a liquid comprising whole blood or a blood fraction. Precipitated fibrinogen is removed from the liquid to form a post-precipitation liquid that is incubated with calcium and a plurality of beads to form a clot. A solution comprising thrombin is separated from the clot. Thrombin prepared thereby can be used as a tissue sealant and in methods of applying a tissue sealant to subject, including application of an autologous tissue sealant. | 11-08-2012 |
20120308550 | Method of Using Fish Plasma Components to Promote Functional Recovery in the Mammialian CNS - A method includes applying thrombin and salmon fibrinogen to injured motor neurons at a central nervous system injury site, thereby enhancing repair and functional recovery of the injured motor neurons, such as by injecting or spraying thrombin and salmon fibrinogen to form a fibrin clot, or by applying a composition including thrombin and salmon fibrinogen. A method of promoting the functional recovery of a patient who has suffered a central nervous system injury includes this method. A composition including thrombin and salmon fibrinogen is adapted to be applied to injured motor neurons at a central nervous system injury site, thereby enhancing repair and functional recovery of the injured motor neurons. | 12-06-2012 |
20120308551 | Protease screening methods and proteases identified thereby - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 12-06-2012 |
20120308552 | Hemostatic bio-material composition and method - The present invention relates to a haemostatic bio-material composition and method for achieving hemostasis. The method for providing hemostasis generally comprises: supplying a dry potassium phosphate based hemostat mixture comprising: monobasic potassium phosphate, a metal oxide, and a tertiary calcium phosphate, wherein the weight percent ratio of monobasic potassium phosphate to metal oxide is between about 3:1 and 1:1; mixing the dry potassium phosphate based hemostat mixture with an aqueous solution forming an activated hemostat slurry; applying an hemostasis-promoting amount of the activated potassium phosphate based hemostat slurry to a site of bleeding; wherein the site of bleeding is in, on, or proximate to bone. | 12-06-2012 |
20130011382 | Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain - The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen. | 01-10-2013 |
20130028883 | Treatment of ischemic episodes and cerebroprotection through Misoprostol - The present invention provides compositions and methods for treating an ischemic episode using misoprostol alone or in combination with anti-thrombotic agents. | 01-31-2013 |
20130034536 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis - Provided herein are methods and compositions comprising bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis. | 02-07-2013 |
20130039902 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE - The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire | 02-14-2013 |
20130045196 | ENZYMATIC WOUND DEBRIDING COMPOSITIONS WITH ENHANCED ENZYMATIC ACTIVITY - The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base. | 02-21-2013 |
20130052184 | GELATINASE INHIBITORS AND PRODRUGS - The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | 02-28-2013 |
20130064806 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 03-14-2013 |
20130064807 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 03-14-2013 |
20130071375 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - The present invention provides methods for treating sepsis comprising administering to an individual an effective amount of a chimeric protein. | 03-21-2013 |
20130084277 | FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE - The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs. | 04-04-2013 |
20130084278 | WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF - The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed. | 04-04-2013 |
20130101575 | LACTOFERRIN SEQENCES, COMPOSITIONS AND METHODS FOR CORNEAL WOUND TREATMENT - The present invention relates to pharmaceutical compositions containing lactoferrin, or fragments of it, and their use in the treatment of wounds, particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C-lobe of lactoferrin, or functionally active fragments or variants thereof. | 04-25-2013 |
20130108610 | Inhibition of Microbial Growth by Aconitase Inhibition | 05-02-2013 |
20130108611 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE | 05-02-2013 |
20130108612 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS | 05-02-2013 |
20130115204 | PREPARATIVE PURIFICATION PROCESS FOR HUMAN FURIN - Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%. | 05-09-2013 |
20130129710 | HEMOSTATIC COMPOSITIONS - The invention discloses a method for producing a hemostatic composition comprising mixing a biocompatible polymer suitable for use in hemostasis and a genipin-type crosslinker, crosslinking said polymer by said genipin-type crosslinker to obtain a crosslinked biocompatible polymer, and finishing said crosslinks polymer to a pharmaceutically acceptable hemostatic composition, new hemostatic compositions and methods for using such compositions. | 05-23-2013 |
20130136731 | Protein Fusion Constructs Possessing Thrombolytic and Anticoagulant Properties - The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation. | 05-30-2013 |
20130149294 | OSTEOGENIC DEVICES AND METHODS OF USE THEREOF FOR REPAIR OF ENDOCHONDRAL BONE, OSTEOCHONDRAL AND CHONDRAL DEFECTS - Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and detects resulting from degenerative diseases such as osteochondritis dessicans. | 06-13-2013 |
20130149295 | FURIN AND BIOLOGICALLY ACTIVE DERIVATIVES THEREOF FOR USE IN THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASE - The present invention relates to the prevention or therapy of inflammatory diseases. More particularly, the invention relates to an isolated polypeptide comprising the subtilisin-like catalytic domain of the furin or a biologically active derivative thereof, for use in the prevention or treatment of an inflammatory disease. | 06-13-2013 |
20130171126 | CROSSLINKED POLYSACCHARIDE BEADS AND THEIR BIOMEDICAL USES - The present inventions relates to beads as biocompatible material adapted for use within the human or animal body. Said beads are highly useful for tissue engineering, in situ tissue regeneration, as well as for drug and/or cells delivery. In addition, said beads may support biotechnological applications such as cell carriers. | 07-04-2013 |
20130189243 | BIOMARKERS FOR ACUTE ISCHEMIC STROKE - The present invention provides methods and compositions for the diagnosis of acute ischemic stroke. The invention further provides methods and compositions for distinguishing acute ischemic stroke from other forms of stroke and TIAs and “stroke mimic” events. Moreover, methods and compositions are provided to facilitate the treatment of acute ischemic stroke patients. | 07-25-2013 |
20130189244 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 07-25-2013 |
20130195837 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY - This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31). | 08-01-2013 |
20130209441 | PROCESS FOR INHIBITION OF CEREBRAL DAMAGE ASSOCIATED WITH ISCHEMIA BY ANTHOCYANINS AND ANTHOCYANIDINS - A process is provided for inhibition of neural damage associated with an ischemic event that includes the administration of anthocyanin compound to a subject. After allowing sufficient time for the anthocyanin compound to reach the situs of the ischemic event, inhibition of neural damage associated with the ischemic event occurs. Neural damage is further inhibited by administration of the anthocyanin compound in conjunction with an agent effective in and specifically including tissue plasminogen activator. The anthocyanin compound in specific embodiments is in pure form or a mixture of two or more anthocyanins, or anthocyanidins or aglycones thereof, with the mixture being a natural product extract. | 08-15-2013 |
20130209442 | WOUND CLEANING CHEMICAL COMPOSITION AND METHOD FOR MANUFACTURING - A wound cleaning chemical composition that includes an unpurified saline solution in the range of 1.5 to 3 grams per cc, a lactoferrin solution in the range of 0.001% to 1.5% by volume, an ethanol solution in the range of 0.05% to 1.5% by volume, a sodium bicarbonate solution in the range of 1.2% to 5.1% by volume and a hypochlorite solution in the range of 0.06% to 4.7% by volume. The wound cleaning chemical composition also includes a method for manufacturing a wound cleaning chemical composition that includes the steps of preparing an unpurified saline solution, adding a hypochlorite solution, an ethanol solution and a sodium bicarbonate solution to the unpurified saline solution and adding a lactoferrin solution. | 08-15-2013 |
20130216518 | COMPOSITION COMPRISING A COMBINATION OF AT LEAST ONE PROTEOLYTIC ENZYME AND AT LEAST ONE LIPOLYTIC ENZYME, FOR USE IN PREVENTING TRIGLYCERIDE SYNTHESIS - The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use as a drug, cosmetic agent, medical device, dietary composition, dietary supplement or nutraceutical, notably for use in preventing or treating obesity, atherosclerosis, type 2 diabetes or for use in preventing or reducing excess weight. | 08-22-2013 |
20130216519 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 08-22-2013 |
20130224179 | PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH - The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. | 08-29-2013 |
20130243747 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME - Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed. | 09-19-2013 |
20130259853 | Treatment of Acute Ischemic Stroke or Intracranial Bleeding with tPA and Carbamylated Erythropoietin - The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin. | 10-03-2013 |
20130259854 | METHODS AND COMPOSITIONS FOR REDUCING THE INCIDENCE OF POST-SURGICAL ADHESIONS - The disclosure relates to a method of reducing the incidence of post-surgical adhesions in a subject undergoing surgery. More specifically, the method relates to reducing the incidence of post-surgical adhesions with the topically administration of activated protein C (APC) to the internal organs and tissues exposed and/or manipulated during surgery. | 10-03-2013 |
20130273028 | PLASMINOGEN AND PLASMIN VARIANTS - The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed. | 10-17-2013 |
20130280234 | Treatment and Composition for Wound Healing - A method and medicament for promoting wound healing in a subject is disclosed. The medicament comprises an effective amount of an agent comprising one or more of;
| 10-24-2013 |
20130280235 | METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS - The invention relates to pharmaceutical compositions comprising tissue kallikrem (TK), and optionally a diabetes drug, a method of screening for a metabolic disorder by determining the concentration of TK and insulin in a biological sample from a test subject, a method of screening for a therapeutic agent for the treatment or prevention of a metabolic disorder, and a method for treating or preventing a metabolic disorder using a pharmaceutical composition comprising TK. | 10-24-2013 |
20130280236 | FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS - The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s). | 10-24-2013 |
20130309221 | HUMAN GROWTH AND DIFFERENTIATION FACTOR GDF-5 - This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. Said compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as for example growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The invention can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders. | 11-21-2013 |
20130315891 | FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS - Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof. | 11-28-2013 |
20130323227 | PHARMACEUTICAL COMPOSITIONS OF TENECTEPLASE - Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke. | 12-05-2013 |
20130330318 | Method for Treating Filtration Failure After Trabeculectomy Surgery - The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these | 12-12-2013 |
20130330319 | CELL MIGRATION MODULATOR - The present invention provides a cell migration regulator capable of promoting or inhibiting cell migration, a method for regulating cell migration, and a pharmaceutical composition comprising such a regulator, etc. The cell migration regulator of the present invention comprises a peptide, a derivative thereof, or a salt of the peptide or the derivative, wherein the peptide comprises the full-length blood coagulation factor IX, a segment derived from the full-length blood coagulation factor IX by removal of the trypsin domain, the light chain of blood coagulation factor IX, or the EGF1 domain of blood coagulation factor IX, or the EGF3 domain of the endothelial cell locus-1 protein. | 12-12-2013 |
20130336956 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 12-19-2013 |
20130344056 | KERATIN BIOMATERIALS FOR TREATMENT OF ISCHEMIA - Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns. | 12-26-2013 |
20140004098 | METHODS OF TREATMENT WITH ELASTASE | 01-02-2014 |
20140004099 | DODECAFLUOROPENTANE EMULSION AS A STROKE AND ISCHEMIA THERAPY | 01-02-2014 |
20140030247 | Modified factor X polypeptides and uses thereof - Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided. | 01-30-2014 |
20140037614 | THERAPEUTIC AND PROPHYLACTIC METHODS, USES AND COMPOSITIONS COMPRISING ANEXIN A5 - The present invention provides a method for the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery, comprising administering a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof to a patient in need of such treatment, Also provided is a pharmaceutical composition comprising a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof for use in the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery. | 02-06-2014 |
20140044701 | Factor VII polypeptides that are modified and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 02-13-2014 |
20140050716 | NOVEL PROCOAGULANT MOLECULAR DECOY FOR TREATING HEMOPHILIA A OR B WITH OR WITHOUT INHIBITOR - The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor. | 02-20-2014 |
20140050717 | Methods for Treating Bleeding Disorders - A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor X1; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor X1-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI. | 02-20-2014 |
20140079684 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 03-20-2014 |
20140079685 | METHOD AND COMPOSITION FOR TREATING A SEROTONIN RECEPTOR-MEDIATED CONDITION - A method and composition for treating serotonin receptor-mediated conditions. | 03-20-2014 |
20140086897 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF - Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | 03-27-2014 |
20140086898 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 03-27-2014 |
20140086899 | DIAGNOSTIC AND PROGNOSTIC ASSAY FOR A CONDITION OR EVENT OF THE VASCULAR SYSTEM - The present disclosure relates generally to the field of diagnostic and prognostic assays for a condition or event of a vascular system such as the cerebrovascular system. An assay is taught herein for monitoring progression of a condition or event of a vascular system such as the cerebrovascular system as well as determining the state or stage of the condition or event. The assay of the present disclosure is also useful in the stratification of a subject based on the stage or development of the condition or event. | 03-27-2014 |
20140093491 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII. | 04-03-2014 |
20140120078 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 05-01-2014 |
20140127185 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS - Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as progesterone or allopregnanolone, and a thrombolytic agent, such as tissue plasminogen activator (tPA). Also described are compositions and methods for reducing the risks of thrombolytic agent treatment using a neuroprotective steroid. | 05-08-2014 |
20140134151 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS - The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor. | 05-15-2014 |
20140134152 | COMPOSITIONS AND METHODS FOR TREATING DIABETES - Embodiments of the present invention relate to compositions and methods of treating patients for type 1 diabetes mellitus (T1D) by administering a therapeutically effective dose of recombinant human KLK1, variants of KLK1, or active fragments thereof. Such patients may be increase risk patients for developing T1D or T1D patients in the Honeymoon Phase. Such treatment may be expected to prevent or delay the onset of T1D, to ameliorate the symptoms of T1D, or to ameliorate the extent to which the T1D manifests. | 05-15-2014 |
20140140979 | Compositions And Methods Of Use of Phorbol Esters For Treatment of Stroke - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects. | 05-22-2014 |
20140147432 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH BLOOD AND LYMPHATIC DISORDERS - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 05-29-2014 |
20140154233 | METHOD OF PURIFYING THERAPEUTIC PROTEINS - The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or Factor VIII and/or von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising fibrinogen and/or Factor VIII and/or VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or Factor VIII and/or VWF which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof. | 06-05-2014 |
20140154234 | METHOD FOR GENERATING THROMBIN - Methods of generating thrombin and methods of applying a clotting tissue sealant to a site on a subject are provided. A blood component comprising platelets can be obtained from the subject. A hypotonic composition is contacted with a solid matrix to form a thrombin-containing liquid, where the hypotonic composition includes water, calcium, a blood component comprising platelets, and optionally a chelator. Calcium is present in the hypotonic composition in an amount greater than the amount of calcium that can be complexed by the chelator. Thrombin-containing liquid is then separated from the hypotonic composition and can be applied to the site on the subject to form a clot, for example, by combination with fibrinogen. | 06-05-2014 |
20140154235 | WOUND DEBRIDEMENT COMPOSITIONS CONTAINING SEAPROSE AND METHODS OF WOUND TREATMENT USING SAME - Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds. | 06-05-2014 |
20140154236 | DEVICES AND METHODS FOR TREATING PAIN ASSOCIATED WITH TONSILLECTOMIES - Described here are devices and methods for treating one or more conditions or symptoms associated with a tonsil procedure. In some variations, a drug-releasing device may be at least partially delivered to one or more tonsillar tissues before, during, or after a tonsil procedure. In some variations, the drug-releasing device may be configured to be biodegradable. In other variations, the drug-releasing device may comprise one or more hemostatic materials or one or more adhesives. The drug-releasing device may be configured to release one or more drugs or agents, such as, for example, one or more analgesics, local anesthetics, vasoconstrictors, antibiotics, combinations thereof and the like. | 06-05-2014 |
20140178356 | Stabilised Solid Compositions of Factor VII Polypeptides - The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature. | 06-26-2014 |
20140186327 | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions. | 07-03-2014 |
20140186328 | NEUROPROTECTIVE POLYPHENOL ANALOGS - The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS. | 07-03-2014 |
20140186329 | POLYPHENOL ANALOGS TO TREAT ISCHEMIA - The present invention provides methods of use of polyphenol compounds for treating, preventing, mitigating and delaying ischemia or a condition where ischemia occurs. In one embodiment, the method comprises providing a polyphenol analog; and administering the polyphenol analog to a subject to treat ischemia or a condition where ischemia occurs. Various embodiments of the present invention are useful for the treatment of patients having, or at risk for, any of (1) ischemic stroke, (2) hemorrhagic stroke, (3) cardiovascular disease, (4) ischemia related spinal cord injury, (5) ischemia in diabetic patients, or (6) embolic stroke. For example, use of the polyphenol compounds can maintain glutathione levels in the patient. | 07-03-2014 |
20140199287 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE - The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire | 07-17-2014 |
20140205587 | Proteases for Degrading Gluten - Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance. | 07-24-2014 |
20140205588 | PLASMINOGEN AND PLASMIN VARIANTS - The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatalytic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed. | 07-24-2014 |
20140212405 | Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions - A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents. | 07-31-2014 |
20140212406 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF - The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | 07-31-2014 |
20140219989 | FACTOR IXA INHIBITORS - The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. | 08-07-2014 |
20140219990 | WOUND CLEANING CHEMICAL COMPOSITION AND METHOD FOR MANUFACTURING - A wound cleaning chemical composition that includes 2 gs natural salt in 100 mls of water forming a natural salt solution, 50 mgs lactoferrin in 100 mls of water forming a lactoferrin solution, 2 gs sodium bicarbonate in 100 mls of water forming a sodium bicarbonate solution and 1 ml of 95.25% hypochlorite in 100 mls of water forming a hypochlorite solution. The wound cleaning chemical composition also includes a method for manufacturing a wound cleaning chemical composition that includes the steps of preparing an natural salt solution, adding a hypochlorite solution and a sodium bicarbonate solution to the natural salt solution and adding a lactoferrin solution. | 08-07-2014 |
20140219991 | TREATMENT AND COMPOSITION FOR WOUND HEALING - A method and medicament for promoting wound healing in a subject is disclosed. The medicament comprises an effective amount of an agent comprising one or more of;
| 08-07-2014 |
20140234290 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF - Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided. | 08-21-2014 |
20140242062 | MODIFIED PROTEASES THAT INHIBIT COMPLEMENT ACTIVATION - Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders. | 08-28-2014 |
20140248257 | COMBINATION THERAPY FOR ISCHEMIA - The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment invoices administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g. by administration of tPA). Administration a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered. | 09-04-2014 |
20140248258 | METHODS FOR IMPROVING GUT HEALTH - The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of | 09-04-2014 |
20140248259 | Compositions and Methods for Modulating Hemostasis - Factor X/Xa variants and methods of use thereof are disclosed. | 09-04-2014 |
20140271606 | METHODS OF USING ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING BLEEDING DISORDERS - Methods of treating bleeding disorders, such as bleeding diseases such as hemophilia, by administering adenosine 2a receptor and/or adenosine 2b receptor antagonists to subjects in need thereof are disclosed. In some embodiments, the methods further include administration of the antagonist with one or more of Factor VIII, Factor IX and Factor XI to treat the bleeding disorder. | 09-18-2014 |
20140271607 | BLOOD COAGULATION FACTOR VII AND VIIA DERIVATIVES, CONJUGATES AND COMPLEXES COMPRISING THE SAME, AND USE THEREOF - A blood coagulation factor VII derivative, a blood coagulation factor VIIa derivative, FacVII and FacVIIa conjugates are prepared by linking a polymer capable of extending the blood half-life to the derivative. FacVII and VIIa complexes each prepared by linking a carrier to the conjugate, genes encoding the FacVII and FacVIIa derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the FacVII and FacVIIa derivatives using the transformants, a method for preparing the FacVIIa conjugate and complex, a FacVIIa complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient are described. | 09-18-2014 |
20140302005 | CHIMERIC FACTOR VII MOLECULES - The present invention relates to chimeric Factor VII polypeptides and methods of using the same. | 10-09-2014 |
20140302006 | SUPPRESSION OF NEUROENDOCRINE DISEASES - The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods. | 10-09-2014 |
20140314736 | NOVEL PATIENT SUBGROUPS FOR THROMBOLYSIS - A method for treating a stroke patient with thrombolysis, wherein prior to treatment the patient is diagnosed in particular for exhibiting cerebral tissue at risk, a cerebral artery occlusion, and/or an absolute “mismatch volume”. | 10-23-2014 |
20140314737 | Blood Biomarker for Early Blood Brain Barrier Disruption in Ischemic Stroke - Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample. | 10-23-2014 |
20140322194 | Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same - Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate. | 10-30-2014 |
20140322195 | Factor IXA Inhibitors - The present invention provides a compound of Formula (I) | 10-30-2014 |
20140322196 | LACTOFERRIN DERIVED PEPTIDES FOR USE AS BROAD-SPECTRUM INHIBITORS OF INFLUENZA VIRUS INFECTION - The present disclosure describes lactoferrin C-lobe and peptides derived thereof used as broad spectrum inhibitors of Influenza virus group 1 and 2 hemagglutination and infection. | 10-30-2014 |
20140328827 | Methods for Fucoidan Purification from Seaweed Extracts - Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration. | 11-06-2014 |
20140341879 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY - This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof wherein the peptide is D-Arg-26-Dmt-Lys-Phe-NH2 (SS-31). | 11-20-2014 |
20140341880 | RISK PREDICTORS FOR ADVERSE PERINATAL OUTCOMES - Methods for assessing a risk of experiencing an adverse perinatal outcome in a subject are described. The methods include determining a level of at least one cytokine in a biological sample from the subject; and comparing the level of the at least one cytokine in the subject's biological sample with a predetermined value based on levels of the at least one cytokine in a biological sample from a population of control subjects, wherein a subject whose level of at least one cytokine is greater than the predetermined line value is at risk of experiencing an adverse perinatal outcome. | 11-20-2014 |
20140341881 | USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES - This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor. | 11-20-2014 |
20140356346 | MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE - The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences. | 12-04-2014 |
20140356347 | NOVEL SERINE PROTEASE VARIANTS - The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer. | 12-04-2014 |
20140363419 | SHORT-ACTING FACTOR VII POLYPEPTIDES - Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding. | 12-11-2014 |
20140369991 | Formulations for Wound Therapy - The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention. | 12-18-2014 |
20140369992 | C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses - The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins. | 12-18-2014 |
20140369993 | STABILISED PROTEIN COMPOSITIONS BASED ON SEMIFLUORINATED ALKANES - The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route. | 12-18-2014 |
20140369994 | METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS - Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia. | 12-18-2014 |
20140369995 | COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION - The present invention provides compositions and methods for treating stroke patients using TCM and a Western medicament used for the treatment of stroke patients. | 12-18-2014 |
20140377247 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA - Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders. | 12-25-2014 |
20150010530 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 01-08-2015 |
20150010531 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VASCULAR DISEASE - The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction. | 01-08-2015 |
20150023947 | MEDICINAL PRODUCTS FOR THE TREATMENT OF BLOOD COAGULATION DISORDERS - A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation. | 01-22-2015 |
20150037314 | Dry Haemostatic Composition - Disclosed is a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. Further disclosed are methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes. | 02-05-2015 |
20150044195 | FVIIa-sTF complexes exhibiting exosite-mediated super activity - Disclosed are disulphide-linked complexes of a soluble Tissue Factor (sTF) variant of SEQ ID NO:3 comprising the mutation G109C and a Factor VIIa variant of SEQ ID NO. 1, comprising the mutation Q64C and a mutation at position M306 that gives rise to a zymogen-like conformation in the Factor VIIa polypeptide. Said complexes may be used for the treatment of a coagulopathy. | 02-12-2015 |
20150050264 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF - The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | 02-19-2015 |
20150064163 | BMP Peptides & Methods of Use - The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition. | 03-05-2015 |
20150064164 | TISSUE DISRUPTION TREATMENT AND COMPOSITION FOR USE THEREOF - The present invention relates to an agent having activity in the treatment of a tissue disruption. In particular the present invention relates to a composition comprising an effective amount of an active fraction having tissue healing properties | 03-05-2015 |
20150071908 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects. | 03-12-2015 |
20150071909 | METHODS AND COMPOSITIONS FOR REDUCING THE INCIDENCE OF POST-SURGICAL ADHESIONS - The disclosure relates to a method of reducing the incidence of post-surgical adhesions in a subject undergoing surgery. More specifically, the method relates to reducing the incidence of post-surgical adhesions with the topically administration of variants of activated protein C with cytoprotective and antiinflammatory activity to the internal organs and tissues exposed and/or manipulated during surgery. The disclosure is also related to reducing the incidence of post-surgical adhesions with the topically administration of a variant of activated protein C with cytoprotective activity and reduced or no anticoagulant activity. | 03-12-2015 |
20150079067 | Pharmaceutical composition for repairing wound and/or regenerating tissue, method and uses thereof - This invention discloses a method to produce a pharmaceutical composition from bloods for repairing wound which don't have to extra add commercial thrombins or non-human thrombins but to manufacture the pharmaceutical composition from bloods for repairing wound directly from bloods. Therefore, the method discloses in this present invention have the effect to avoid the rejection reaction of the treated patients and to reduce the costs of production, and furthermore to decrease medical costs and the burden of patients. | 03-19-2015 |
20150079068 | FORMULATIONS OF RECOMBINANT FURIN - The present application provides stabilized formulations of furin (e.g., rfurin) containing a sugar, sugar alcohol, and/or non-ionic surfactant. As compared to non-stabilized compositions, the furin formulations disclosed herein retain greater amounts of furin activity and monomeric furin content, while reducing furin aggregation when stored and/or subjected to mechanical stress. Also provided are methods for stably diluting furin (e.g., rfurin) compositions. | 03-19-2015 |
20150093372 | GELATINASE INHIBITORS AND PRODRUGS - The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | 04-02-2015 |
20150118218 | IMMOBILIZED PROTEIN SYSTEM FOR RAPID AND ENHANCED MULTIPLEXED DIAGNOSTICS - The disclosure relates to methods of detecting a neural injury biomarker in a biological sample. The method includes subjecting a biological sample to an assay disclosed that produces a measurable signal and detecting the measurable signal. The presence or absence of the measurable signal indicates the presence or absence of the neural injury biomarker in the sample, and thereby diagnosing a subject as having a neural injury. The disclosure further relates to methods of determining the state of a subject's neural injury. Further disclosed are systems and devices useful in carrying out the methods disclosed. | 04-30-2015 |
20150118219 | USE OF SEAPROSE TO REMOVE BACTERIAL BIOFILM - Disclosed are compositions and methods for their use in disrupting a bacterial biofilm present on a surface, comprising applying a composition that includes Seaprose to the bacterial biofilm, wherein application of the composition to the bacterial biofilm disrupts the matrix of the bacterial biofilm. | 04-30-2015 |
20150125440 | METHOD FOR IMPROVED FIBRIN SEALING - The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue. | 05-07-2015 |
20150147312 | DRY PAD COMPRISING THROMBIN AND PECTIN - The present invention is directed to a dry pad comprising pectin, a divalent cation and thrombin and to its preparation. Preferably, the density of pectin in the dry pad of the invention ranges from about equal to or higher than 1% to lower than 7% (w/v). The pad according to the invention comprises pectin having a low methoxyl content. | 05-28-2015 |
20150297687 | PROTEASE COMPOSITIONS FOR THE TREATMENT OF DAMAGED TISSUE - The invention is directed to compositions containing one or more proteases that are beneficial in the treatment of damaged tissue, wounds and inflammation. The compositions of the invention modulate the levels and activity of proteins that are present at wound and inflammation sites and promote the repair of damaged tissue. | 10-22-2015 |
20150307863 | METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS - Factor IX proteins are described with an increase in the number of glycosylation sites and other modifications to provide Factor IX proteins that have higher specific activity and a longer useful clotting function relative to wild type or non-modified Factor IX protein. | 10-29-2015 |
20150307865 | COAGULATION FACTOR VII POLYPEPTIDES - The present invention relates to modified coagulation Factor VII (Factor VII) polypeptides having coagulant activity as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment. | 10-29-2015 |
20150315264 | PROCESS FOR PURIFYING LACTOFERRIN FROM MILK AND PRODUCTS THEREOF - The invention provides a process for purifying lactoferrin from milk, the process comprising subjecting the milk to filtration to separate it into a retentate fraction comprising lactoferrin and a permeate fraction comprising growth factors and/or RNAses, wherein prior to and/or during filtration the milk is subjected to salt treatment such that growth factors and/or RNAses flow into the permeate. The invention also provides lactoferrin obtained from the process of the invention and uses thereof. | 11-05-2015 |
20150322421 | TREATMENT FOR AIRWAY CAST OBSTRUCTION - The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent. | 11-12-2015 |
20150329846 | Recombinant Elastase Proteins and Methods of Manufacturing and Use Thereof - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 11-19-2015 |
20150329847 | FUSION PROTEIN COMPRISING GRANZYME B AND USE THEREOF - A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein. | 11-19-2015 |
20150337284 | FACTOR IX VARIANTS - Variants of factor IX with increased membrane binding affinity, and the use of such variants for treating factor IX deficiency, are described. | 11-26-2015 |
20150343033 | USE OF ANTIDOTES TO COAGULATION INHIBITORS INDICATED IN THE PREVENTION OR TREATMENT OF THROMBOEMBOLIC PATHOLOGIES - The use of factor Xa in the prevention or treatment in a patient, in particular a human being or an animal, of haemorrhagic events induced by taking anticoagulants. | 12-03-2015 |
20150343064 | Stabilised Solid Compositions of Factor VII Polypeptides - The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature. | 12-03-2015 |
20150344863 | SHORT-ACTING FACTOR VII POLYPEPTIDES - Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding. | 12-03-2015 |
20150353911 | CHIMERIC CLOTTING FACTORS - The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors. | 12-10-2015 |
20150353912 | METHODS FOR TREATING AND PREVENTING RADIATION INJURY USING ACTIVATED PROTEIN C POLYPEPTIDES - Methods of treating and preventing radiation injury are provided by the present invention. In particular, provided herein are methods comprising administering to a subject an Activated Protein C (APC), Plasma Zymogen Protein C (PC), or a variant thereof to treat or prevent radiation injury and to reduce chemical toxicity in subjects receiving myelosuppressive therapy. | 12-10-2015 |
20150359859 | A METHOD OF VIRUS INACTIVATION IN COMPOSITION COMPRISING FACTOR VII - The present invention relates to a method for inactivating viruses in a composition comprising blood coagulation factor VII, and more particularly, to a method for inactivating viruses comprising adding a surfactant to a composition comprising blood coagulation factor VII or a derivative thereof and a method for preparing a virus-inactivated composition comprising blood coagulation factor VII or the derivative thereof. | 12-17-2015 |
20150359926 | Methods And Compositions For Medical Articles Produced From Proteinaceous Compounds - The invention disclosed herein provides compositions and methods for biocompatible biomaterials with improved control of microorganisms, improved biocompatibility, lower toxicity, and reduce vCJD transmission potential. These combined benefits cascade to provide improved efficacy, improved patient compliance and improved performance, while limiting clinical complications in treatment. | 12-17-2015 |
20150366952 | METHODS FOR REDUCING FIBROSIS INDUCED BY PERITONEAL DIALYSIS - The disclosure relates to a method of preventing, inhibiting, or reducing fibrosis, the incidence of fibrosis or the progression of fibrosis associated with peritoneal dialysis, during or after peritoneal is administered. More specifically, the methods relates to using intraperitoneal administration of activated protein C (APC) possessing cytoprotective or anti-inflammatory activity, to reduce the incidence or progression of fibrosis associated with peritoneal dialysis. The method is demonstrated using wild type APC and a mutant APC possessing cytoprotective or anti-inflammatory activity but lacking anti-coagulant activity. | 12-24-2015 |
20150366953 | GLAUCOMA TREATMENT - Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector. | 12-24-2015 |
20150367022 | PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS - Described is a process for making a dry and stable hemostatic composition, said process comprising
| 12-24-2015 |
20150368630 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME - Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed. | 12-24-2015 |
20150374804 | TREATMENT OF DISEASES RELATED TO HYPERACTIVITY OF THE COMPLEMENT SYSTEM - Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described. | 12-31-2015 |
20150376109 | Compositions and methods of use of Phorbol Esters for treatment of stroke - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects. | 12-31-2015 |
20160000704 | FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS - Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof. | 01-07-2016 |
20160000863 | HEMOSTATIC COMPOSITIONS - The invention provides a composition comprising a combination of lipidated tissue factor and thrombin, wherein the amount of thrombin is comprised from 1 to 30 IU per gram of composition, and the amount of lipidated tissue factor is comprised from 5 to 150 ng per gram of composition. The present invention also provides pharmaceutical or veterinary compositions as well as hemostatic compositions. The compositions of the invention are useful in the treatment of hemorrhages. | 01-07-2016 |
20160002617 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 01-07-2016 |
20160009748 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | 01-14-2016 |
20160010074 | PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY | 01-14-2016 |
20160015792 | POWDER FORMULATION COMPRISING THROMBIN AND FIBRINOGEN - The invention relates to sterile powder compositions suitable for medical use comprising thrombin and fibrinogen, and to methods for producing the same, wherein the thrombin powder is produced from a liquid feedstock, wherein the feedstock comprises a solution or a suspension of thrombin, preferably a solution, wherein the powder is produced by removal of liquid by a process selected from aseptic spray drying or aseptic fluid bed drying, and wherein the powder resulting from removal of liquid from the feedstock exhibits at least 80% of the thrombin potency or activity of the liquid feedstock, and wherein the fibrinogen powder is produced by removal of liquid from a feedstock, wherein the feedstock comprises a solution or a suspension of fibrinogen, preferably a solution, by aseptic spray drying or aseptic fluid bed drying, and wherein said composition is packaged as a sterile final pharmaceutical product for medical use. | 01-21-2016 |
20160018399 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION - This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided. | 01-21-2016 |
20160024487 | THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES - The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX “IVGG” motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia. | 01-28-2016 |
20160030501 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY - This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31). | 02-04-2016 |
20160046957 | PRODUCTION OF FULLY PROCESSED AND FUNCTIONAL FACTOR X IN A FURIN-SECRETING MAMMALIAN EXPRESSION SYSTEM - Disclosed herein are methods for production of fully-processed mature Factor X in an expression system producing a controlled amount of furin between 50 U/mL and 300 U/mL of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and Factor X. | 02-18-2016 |
20160058848 | TREATMENT OF CARDIO-RENAL DISEASE USING PCSK6 - A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator. | 03-03-2016 |
20160076018 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME - Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed. | 03-17-2016 |
20160082145 | SEALANT COMPOSITIONS - The invention provides a combination comprising thrombin, fibrinogen, and lipidated tissue factor, as well as sealant compositions comprising thereof, and their use as a sealant agent as well as in the treatment of hemorrhages. The combination and compositions of the invention shows improved hemostatic properties and, at the same time, the quality of the clot formed is so consistent that the sealant efficiency is improved over those sealant compositions of the prior art. | 03-24-2016 |
20160089382 | STEROIDAL NITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA, ALZHEIMER AND PARKINSON DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS - The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis. | 03-31-2016 |
20160101162 | SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa - The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent. | 04-14-2016 |
20160101163 | Stabilised Compositions of Factor VII Polypeptides - The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature. | 04-14-2016 |
20160106818 | HUMAN COAGULATION FACTOR LIGHT CHAIN PROTEIN AND USE OF THE SAME - In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The human coagulation factor light-chain proteins are light chain proteins of human coagulation factors VII, IX, and X, as well as a protein having homology of more than 50% thereof. | 04-21-2016 |
20160106883 | Processes For Mixing Fibrinogen and Thrombin Under Conditions That MinimizeFibrin Formation While Preserving Fibrin-forming Ability, Compositions Producedby These Processes, and the Use Thereof - Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component. | 04-21-2016 |
20160114009 | Proteases Able to Hydrolyze Gluten Peptides and Proteins at Acidic PH, from the Actinomycete Actinoallomurus - The invention relates to a new family of proteolytic enxymes having the ability to hydrolize at a pH between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an | 04-28-2016 |
20160121036 | EXTEMPORANEOUS PREPARATION OF AUTOLOGOUS FIBRIN - An Autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically. | 05-05-2016 |
20160122739 | FACTOR IX VARIANTS AND METHODS OF USE THEREFOR - Modified Factor IX (FIX) polypeptides, nucleic acid encoding the same, and methods of generating modified Factor IX polypeptides are provided. Also provided are pharmaceutical compositions that contain the modified Factor IX polypeptides, methods of treatment using modified Factor IX polypeptides, and assay for Factor IX activity. | 05-05-2016 |
20160122740 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND METHOD FOR ITS PRODUCTION - Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide. | 05-05-2016 |
20160137719 | PROCESS FOR PRODUCING HIGH PURITY FIBRINOGEN AND THROMBIN FOR FIBRIN SEALANT - The present invention relates to a fibrin sealant kit comprising purified fibrinogen and thrombin. The invention particularly relates to an improved chromatographic process for the purification of thrombin and fibrinogen components devoid of any significant plasminogen and other impurities. The absence of plasminogen facilitates the exclusion of a proteolytic inhibitor (aprotinin) from among the kit components. | 05-19-2016 |
20160137999 | SUPPRESSION OF ITCH - The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a SNARE protein in an itch-specific DRG neuron or a pruriceptor; a Targeting Moiety (TM) that is capable of binding to a Binding Site on the itch-specific DRG neuron or a pruriceptor, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the itch-specific DRG neuron or a pruriceptor, and wherein said itch-specific DRG neuron or a pruriceptor expresses said SNARE protein; and a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the itch-specific DRG neuron or a pruriceptor; with the proviso that the polypeptide is not a clostridial neurotoxin (holotoxin) molecule. | 05-19-2016 |
20160144001 | METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS - The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA. | 05-26-2016 |
20160145598 | FACTOR X MUTANTS - The present invention concerns a protein comprising a mutated sequence of SEQ ID No. 1, said mutated sequence of SEQ ID No. 1 comprising at least one mutation A, A′, B, C or C′, in which:
| 05-26-2016 |
20160151444 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY | 06-02-2016 |
20160151464 | LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN | 06-02-2016 |
20160152965 | TRANSGENIC FACTOR VII HAVING A SPECIFIC N-GLYCOSYLATION AND SUBSTANTIALLY HOMOGENOUS ISOELECTRIC POINT | 06-02-2016 |
20160158407 | Dry haemostatic composition - The present invention relates to a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. The invention further relates to methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes. | 06-09-2016 |
20160166656 | Compositions and Methods for Treating Celiac Sprue Disease | 06-16-2016 |
20160177286 | GLA-DOMAINLESS FACTOR X | 06-23-2016 |
20160184414 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE - The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by adminstration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | 06-30-2016 |
20160187338 | METHODS AND COMPOSITIONS FOR DETECTING COAGULATION INHIBITORS - The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabigatran in the sample. | 06-30-2016 |
20160194621 | Compositions and Methods for Treating Celiac Sprue Disease | 07-07-2016 |
20160199460 | COMPOSITIONS FOR REDUCING THE DELETERIOUS EFFECTS OF STRESS AND AGING | 07-14-2016 |
20160250284 | METHODS FOR TREATING RESTENOSIS USING ANNEXIN A5 | 09-01-2016 |
20160375109 | COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE - The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa. | 12-29-2016 |
20160375172 | FLOWABLE COLLAGEN-BASED HEMOSTAT AND METHODS OF USE - The invention relates to methods for fabricating a flowable hemostatic composition. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents. | 12-29-2016 |
20160376578 | SHORT-ACTING FACTOR VII POLYPEPTIDES - Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding. | 12-29-2016 |
20170233711 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | 08-17-2017 |
20180021298 | A METHOD FOR IMPROVING FEED DIGESTIBILITY AND GROWTH PERFORMANCE | 01-25-2018 |
20180021416 | TREATMENT OF DISEASES RELATED TO HYPERACTIVITY OF THE COMPLEMENT SYSTEM | 01-25-2018 |
20180023071 | PEPTIDES DERIVED FROM HUMAN PCSK9 CATALYTIC DOMAIN AND USES THEREOF FOR PROMOTING LDL-R ACTIVITY | 01-25-2018 |
20190142780 | USE OF ISOTHIOCYANATE COMPOUNDS | 05-16-2019 |
20220133891 | HEMOSTATIC MICROSPHERES - Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests. | 05-05-2022 |